Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036341 (schizophrenia)
 60,220 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

51 patients were observed. Schizophrenia was diagnosed in 31 patients and endogenous depression in 20 cases. All the patients had extrapyramidal and somato-vegetative side effects of neuroleptics and antidepressive drugs, and were resistant to conventional corrective therapy for at least a period of 3 weeks. In addition to current treatment of both basic disease and adverse effects, cerebrolysin was administered (5-10 ml i.v./dr, during 28 days) and magme B6 (20-30 ml per os during 21 days). By the treatment end-point either moderate or marked reduction of extrapyramidal disorders (according to ESRS) was observed in 74.4% of patients treated by cerebrolysin and in 72.2% treated by magne B6; somato-vegetative adverse effects reduced (by SARS) in 85.8% and in 83.8% respectively. Both drugs showed equally high efficacy against hyperkinetic and cardiovascular side effects (symptoms relief was in 59-62% and 65-69%, respectively). Cerebrolysin is more preferable in cases of side vegetative events, dysomnia and dysuria; magne B6 was more effective in correction of akineto-hypertonic and hyperkinetic-hypertonic syndromes as well as in cholinolytic side effects.
 ...
PMID:[Cerebrolysin and magnesium-B6 in the treatment of side effects of psychotropic drugs]. 1153 Apr 57